Benign Congenital Hypermobility

Ross Hauser, MDRoss Hauser, MD

Benign Congenital Hypermobility (BCH) is generalized joint hypermobility (loose joints in the entire body) due to ligamentous laxity occurs in about five percent of the population. This may be a genetic problem.

Affecting individuals over 40 years of age, typically these people have recurrent joint problems and almost universally suffer from chronic pain. The end result of this condition is often diffuse osteoarthritis.

People with benign congenital hypermobility are also prone to bone dislocation. Hypermobile joints are exhibited by bending the elbow or knee past the neutral position, touching the floor with the palm while bending at the waist, and touching the thumb to the forearm In subtler cases, this condition can only be determined by a physical examination—one of the reasons it is not diagnosed by most physicians. Most physicians are not trained how to adequately examine for joint mobility and Ligament laxity -another reason why a person with diffuse body pain should be evaluated by a physician familiar with the technique of Prolotherapy.

Prolotherapy treatment is the treatment of choice for benign congenital hypermobility because it strengthens the connective tissue to “normal” or “better than normal” condition, preventing over extension of joints. It is recommended that all hypermobile joints be treated to prevent the formation of arthritis. Patients with chronic pain from diffuse body ligamentous laxity require more than the normal four Prolotherapy inection sessions. Patients suffering from BCH may also require some Prolotherapy in the future for maintenance purposes.

Find a Doctor Near You
If you found this article interesting and would like to find out if you are a good Prolotherapy candidate, click here to search for Regenerative Medicine doctors in your area.